Background
Neurologists in outpatient practice routinely care for patients with very different clinical needs, often in the same afternoon. Cognitive evaluation is one area where that breadth creates a practical challenge: the same clinical question of “How is this patient’s cognition, and has it changed?” arises across conditions as different as early Alzheimer’s disease, post-concussion syndrome, and adult ADHD.
Historically, brief paper-based tools like the Mini-Mental State Examination (MMSE) and Mini-Cog provided a quick cognitive snapshot at the point of care. They remain useful as basic screens, but they have meaningful limitations due to the inability to drill down into individual cognitive domains, and they don’t provide normative context. Ultimately, for a clinician trying to track a patient’s trajectory over time, they fall short.
Digital cognitive assessment tools have addressed some of these gaps, but many platforms are narrow in scope and do not provide a holistic solution to support the entire cognitive care workflow across various patient needs.
Practice Context
Dr. Jontel Pierce is a board-certified neurologist with a special interest in headache disorders and concussion. Her outpatient neurology practice reflects the range of conditions encountered in general neurology, including patients presenting with memory complaints and possible early cognitive decline, individuals referred following head injury — including workers’ compensation and personal injury cases — and adults seeking evaluation for attention and concentration difficulties. Cognitive assessment is a routine part of care across all three groups.
Dr. Pierce’s approach to cognitive evaluation has evolved over time. Paper-based screening tools gave way to an earlier digital platform, but it lacked the normative values that help provide additional context for clinicians. BrainCheck was subsequently adopted as the practice’s standard cognitive assessment tool and is now used consistently across all patient populations requiring cognitive evaluation.
How BrainCheck Assess Is Used
Across all three patient groups, the clinical value of BrainCheck starts with the same principle: a composite score tells you that something may be off, but domain-level assessment tells you where. Knowing whether a deficit involves memory encoding, processing speed, executive function, or attention can help shape the diagnostic workup, the conversation with the patient, and the monitoring plan.
Mild Cognitive Impairment and Alzheimer's Disease
For patients presenting with cognitive complaints, BrainCheck Assess is used to establish an objective baseline at the time of initial evaluation. The domain-level output helps Dr. Pierce characterize the nature of the presentation before a diagnosis is made and informs decisions about further workup.
A key element of Dr. Pierce’s protocol is how she handles the patient whose scores fall in the average or low-average range, but who reports that they don’t feel cognitively like themselves. Rather than dismissing the subjective complaint, she uses it as a trigger for a more comprehensive workup, which can include ordering biomarker testing, labs, and imaging.
Following a diagnosis, BrainCheck is repeated every six to nine months. The serial data allows Dr. Pierce to track disease trajectory and evaluate whether any interventions are having a measurable effect. The protocol applies to patients with MCI and mild Alzheimer’s disease.
Concussions and TBI
Concussion evaluation is a particular focus of Dr. Pierce’s practice, and it’s a context where objective cognitive documentation carries significant weight.
Her patient population includes individuals in standard clinical follow-up after head injury as well as those involved in personal injury litigation and workers’ compensation cases, where the medical record has direct practical consequences.
BrainCheck Assess provides a standardized measure of post-injury cognitive status. Serial assessments over the course of recovery give Dr. Pierce objective data to support and document cognitive status at each stage of care.
Adult ADHD
For adults presenting with attention and concentration difficulties, BrainCheck Assess is administered before any pharmacologic treatment is initiated. This pre-treatment baseline serves a dual purpose: it gives Dr. Pierce an objective picture of which cognitive domains are affected prior to intervention, and it creates a reference point for evaluating treatment response over time.
In adult ADHD, where symptom reporting can be inconsistent and subjective, having a documented cognitive baseline adds clinical rigor to the evaluation and monitoring process. Domain-specific data, including attention and processing speed, allows Dr. Pierce to assess whether treatment is producing measurable cognitive change, rather than relying on symptom reports alone.
Clinical Value
What makes BrainCheck effective across these three populations is less about any single feature and more about what the output allows a clinician to do. Results are benchmarked against population norms stratified by age and education level, and the platform generates domain-level scores.
For a clinician moving between patients with very different presentations, that interpretive layer is a meaningful practical advantage — though the scores are a starting point, not a directive. BrainCheck surfaces the data and context; the clinician determines what it means for that patient and what happens next.
Key Takeaways
Dr. Pierce’s implementation illustrates what cognitive assessment looks like when it’s built into a general neurology practice across multiple patient populations. Key elements include:
-
Cross-population applicability: BrainCheck Assess serves MCI and Alzheimer’s disease, concussion and TBI, and adult ADHD populations within a single, consistent workflow, eliminating the need for separate tools or parallel processes for each patient group.
- Domain-level specificity: Multidomain assessment enables Dr. Pierce to characterize the nature of a patient’s cognitive presentation, not just flag that something may be abnormal. That specificity directly shapes clinical decision-making in each population.
- Longitudinal monitoring as the clinical standard: Whether tracking cognitive trajectory in a neurodegenerative disease, documenting recovery from concussion, or evaluating treatment response in ADHD, serial assessment against a consistent baseline is what makes cognitive data actionable over time.
- Normative context built into the report: Population-stratified data embedded in BrainCheck’s output helps aid interpretation for clinicians.
